Merck & Co. Inc. (MRK) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for MRK is $138.80 — 9.5% above the latest price of $126.81.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for Merck is supported by its diversified product portfolio and a strong late-stage pipeline, including promising assets like Winrevair for pulmonary hypertension and Ohtuvayre for COPD. Strategic acquisitions, such as Verona Pharma, Cidara Therapeutics, and Terns Pharmaceuticals, are expected to build new growth pillars with a potential commercial opportunity exceeding $50 billion by the mid-2030s. The subcutaneous formulation of Keytruda (Keytruda Qlex) is also expected to extend patent exclusivity and drive growth. Furthermore, a Discounted Cash Flow (DCF) analysis suggests that Merck may be undervalued, and the company maintains a reliable dividend program.
Bear Case
The primary risk for Merck is the impending patent cliff for Keytruda in 2028, which generated nearly $29.5 billion in sales in 2024, accounting for approximately 46% of the company's total revenue. The loss of exclusivity for other key franchises like Lenvima (2025), Januvia (2026), Lynparza (2027), and Gardasil (2028) further compounds revenue pressures. Additionally, the company faces intensifying global pressure on drug pricing from policymakers and insurers, which could erode future revenue growth and compress net margins. High debt levels and significant reliance on a few flagship drugs also present risks.
Model-assessed risk level: Medium
Key Catalysts to Watch
Continued strong demand for Keytruda in existing and new indications, especially in earlier-stage cancers and through combination therapies.
Successful launch and label expansions of new products like Winrevair and Keytruda Qlex.
Advancements and approvals from the late-stage pipeline, particularly from recent acquisitions.
Global expansion in human health and animal health sectors.
Successful execution of the human health segment restructuring, separating oncology from specialty and infectious diseases.
Technical Backdrop
RSI-14
68.4
50-Day MA
$118.31
200-Day MA
$96.95
From 52-Wk High
0.0%
Full momentum breakdown: Is MRK overbought or oversold?
Model Notes
Merck & Co., Inc. (MRK) is a prominent pharmaceutical company with a robust oncology franchise, anchored by Keytruda, alongside a diversified portfolio that includes vaccines and animal health products. The company is actively working to replenish its pipeline and mitigate the impact of the impending Keytruda patent cliff in 2028 through strategic acquisitions and new product development. Despite some valuation concerns, analysts generally maintain a positive outlook for the stock.
The technical outlook for MRK appears strongly bullish, with the share price trading above its 5, 20, 50, and 200-day exponential and simple moving averages, indicating consistent buying pressure. The Moving Average Convergence Divergence (MACD) indicator also suggests a 'Buy' signal. However, some indicators like the Slow Stochastic and Williams %R are showing overbought conditions, and the Relative Strength Index (RSI) is in a neutral to buy range.
Current Street Context
July 6, 2026The AI price target for Merck & Co. Inc. is $138.80. The company's next earnings report is estimated for August 4, 2026. Analysts are projecting a Q2 2026 EPS of $0.30. Looking ahead, Merck's earnings are expected to grow significantly by 90.17% next year, with EPS projected to increase from $5.19 to $9.87 per share. Wall Street analysts generally hold a 'Moderate Buy' consensus rating, with an average price target of $131.83. While Cantor Fitzgerald reiterated a 'Neutral' rating with a $120.00 price target on July 6, 2026, other firms maintain 'Buy' or 'Outperform' views. The AI price target is above the current price, aligning with the overall positive analyst outlook driven by a diversified pharmaceutical portfolio and a robust pipeline.
Frequently Asked Questions
What is the price target for MRK?
How is this forecast generated?
How accurate are stock price predictions?
Will MRK stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews MRK’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on MRK
Merck & Co. Inc. Overview
Price, chart, analysis & financials
MRK: Overbought or Oversold?
Updated daily
MRK: Why Is It Moving?
Updated daily
MRK: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers